Principal Investigator Contact Information				
Investigator's Name				
Investigator's Title				
Institution/Organization				
Office Address				
Phone				
Fax				
Email				
Curriculum Vitae (CV)	CV attached, initialed and dated within prior 2 years			
	CV date: N/A			

Complete the form below electronically and attach specified documentation.

Study Specifications(1)				
Sponsor/Budget (in the case of undecided, describe a plan)				
Potential conflict of interest (COI): follow COI rule of JSMO	not present	present (descril	ped in JSMO format)	
Approval of IRB	Yes	No		
Title of Proposal/Protocol				
Study Drug/Device				
Study Type (e.g. Phase, in vitro, registry, etc.)	Please specify study typ	e: If 'Other	, please specify:	
Design	Number of Arms:	·		
	Number of Cohorts:	·		
	Randomized `	Yes 1	No	
	Stratified If 'Yes", please specify t		No on:	
	Type of control group:			
	If 'Other', please specify	<i>y</i> :		
			No	
	If 'Yes", please specify t	ype of blind:		
Patient Population (e.g., Cancer unknown primary with X gene mutation)				
Number of Sites/Countries	Geographic scope:			
	Total No. Sites:		Total No Countries:	
	List All Planned Countrie	es:		

Study Specifications(2)		
Sample Size	Number of patients to be evaluated across all arms/cohorts:	
	Number of patients within above total to receive drug/device:	

Regulatory & Institutional Review Board/Committee Review Process (IRB, EC, etc.)				
Board/Committee Review	What type of board approval will be required for this study?			
*As required per local regulations	If 'Other', please specify:			
	How often does the review board or committee meet? Comments:			
Regulatory Authority	Will this study be submitted to a Regulatory Authority? No Yes			
	PMDA FDA EMA			
Other comments related to approval requirements				

Timelines				
Abstract or Manuscript Journal Submission or CSR	Approximate target month/year:			
For retrospective or in vitro studies, summarize timelines				

Study Synopsis

Requestor must either attach Study Synopsis or, to the extent relevant, add the details in text form below.

See details below

See attached Synopsis

- Abstaract
- · Background, study rationale and unmet medical need
- Study population (detailed description of therapeutic area, patient type, setting, type of procedure if applicable, etc.)
- Hypothesis
- Study objective(s) (list as many as apply)
- Timelines (including all phases of a multi-phase study)
- · Methodology/sequence of procedure
 - Screening period (if retrospective/prospective data evaluation, describe the process for screening charts for eligibility)
 - Treatment period (if using drug on-formulary for a retrospective/prospective data evaluation, please specify standard of care followed)
 - Follow-up period (if retrospective/prospective data evaluation, specify any part of patient care post-treatment or procedure for which data will be collected from the charts, including in a post-op area or post-48 hours, etc.)
- Clinical laboratory or other assessments
- · Brief description of any disease state or quality of life measures that will be measured
- · Inclusion and exclusion criteria
- Treatment (dose and administration)
- · Duration of treatment
- Reference therapy (dose and administration)
- · Concomitant and prohibited medications
- Outcomes/endpoints (primary, secondary, exploratory)
- Statistical analyses/assumptions (Describe presence or absence of advice of the statistician as well)
- Schedule of assessments
- Flow diagram (if available)
- · Informed consent
- · Study assessment
- · SAE reporting